Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells
Prolonged remission of hypercortisolism with steroidogenesis inhibitors has been described in patients with ectopic adrenocorticotropic hormone (ACTH) syndrome. The anti-proliferative and pro-apoptotic effect of ketoconazole in human cancer cells was previously suggested. The aim of this study was to explore the effects of ketoconazole on ACTH-producing and non-ACTH-producing neuroendocrine tumor (NET) cell lines. The effects of ketoconazole alone, and in combination with somatostatin analogs, were evaluated in two human cell lines: DMS-79 (ectopic ACTH-producing small cell lung carcinoma) and BON-1 (human pancreatic NET). Total DNA measurement, apoptosis, cell cycle, chromogranin A (CgA)/proopiomelanocortin (POMC) expression by qRT-PCR, serotonin, CgA, and ACTH secretion assays were performed. In both cell lines, ketoconazole significantly suppressed cell growth and colony formation in a dose and time-dependent manner. The effect in DMS-79 was primarily cytotoxic, while it was more apoptotic in BON-1 cells. Ketoconazole also induced increase in G0/G1 phase in both cell lines and arrest in phase G2/M of BON-1 cells. Ketoconazole did not affect the secretion of serotonin, CgA, ACTH, or the mRNA expression of CgA and POMC. Decreased serotonin secretion was observed after the combination treatment with pasireotide. These results suggest a direct effect of ketoconazole on cell proliferation, apoptosis, and cell cycle in both ACTH- and non-ACTH-producing NET cells.
KeywordsKetoconazole Combined therapy Neuroendocrine tumors Proliferation Secretion
Neuroendocrine tumors (NETs) are a heterogeneous family of neoplasms derived from neuroendocrine cells with a wide spectrum of clinical behavior . NETs can occur sporadically or as a result of hereditary predisposition syndromes . Their capacity to secrete peptide hormones divides them in functioning and non-functioning tumors .
One of the most uncommonly secreted hormones is adrenocorticotropic hormone (ACTH) [3, 4], resulting in hypercortisolism and ectopic ACTH syndrome (EAS). EAS is a form of Cushing syndrome (CS) associated with overt malignancies or indolent tumors, including neuroendocrine tumors of the lungs, thymus, and gastrointestinal tract [3, 4, 5, 6]. The management of patients with EAS requires strict control of hypercortisolism as soon as the diagnosis is established, in order to avoid related complications [3, 7, 8]. In EAS patients, initial resection of the primary lesion is the first-line treatment option. However, in some cases, surgery is not possible or successful and in other cases, the source of ectopic ACTH is not identified [8, 9]. For these patients, medical treatment with steroidogenesis inhibitors including ketoconazole and bilateral adrenalectomy represents alternative therapeutic options [10, 11, 12].
Ketoconazole is widely used for medical treatment of CS and can improve clinical signs, symptoms, and comorbidities . Ketoconazole impairs adrenal and gonadal steroidogenesis by inhibiting side-chain cleavage, 17,20-lyase, and 11-β hydroxylase enzymes . Because cortisol production is often very high in EAS, ketoconazole may be less effective in controlling hypercortisolism in EAS patients compared with Cushing disease patients . However, the drug could exert additive effects in the control of patients with severe hypercortisolemia . A direct effect of ketoconazole on tumoral ACTH secretion has been suggested [14, 15], since its use in some EAS cases has been followed by prolonged remission of hypercortisolemia [14, 15, 16]. Ketoconazole also reduces ACTH secretion from thymic tumor cells in culture , suggesting a dual (direct/indirect) action of ketoconazole on EAS tumors.
Some ectopic ACTH-producing tumors express somatostatin receptors, suggesting a putative role of somatostatin analogs (SSA) for reducing ACTH production. Octreotide inhibits the release of ACTH in some patients with Nelson’s syndrome and EAS from metastatic gastroenteropancreatic-NETs, small cell lung carcinoma, carcinoids, and medullary thyroid carcinoma [18, 19, 20]. However, in clinical practice, the effect of SSA is limited, but their use has been suggested when other inhibitors of steroidogenesis fail or when parenteral administration is required .
Despite the development of new therapeutic options in NETs, treatment strategies are still limited. As such, it is necessary to develop novel therapeutic strategies. In this scenario, we aimed to evaluate additional, not previously described in vitro effects of ketoconazole as monotherapy, as well as in combination with SSA on proliferation and hormonal secretion of ACTH-producing and non-ACTH-producing neuroendocrine tumor cell lines, in order to determine potential off target effects of ketoconazole on NET cells.
Materials and Methods
We used the human small cell lung carcinoma cell line DMS-79 and the human pancreatic neuroendocrine tumor cell line BON-1. The cell line DMS-79 (ATCC-CRL-2049™, Manassas, VA, USA) was isolated from pleural fluid of an ACTH-producing small cell lung carcinoma. The BON-1 cell line was a kind gift of Dr. Townsend (The University of Texas Medical Branch, Galveston, TX, USA) and was established from a lymph node metastasis of a human functional pancreatic neuroendocrine tumor. Both cell lines were routinely cultured in 75- cm2 flasks (Greiner bio-one, The Netherlands) at 37 °C in a 5% CO2 incubator.
BON-1 cells were cultured in DMEM/F12 (GIBCO Biocult Europe, Breda, The Netherlands) containing 10% FCS, l-glutamine, fungizone (0.5 mg/L), and penicillin (100 U/mL) (Bristol-Myers Squibb, Woerden, The Netherlands). Cells were harvested with trypsin (0.05%)–EDTA (0.53 mM) and resuspended in culture medium. Cell viability always exceeded 85%. For the serotonin and chromogranin measurements, BON-1 cells were cultured in DMEM/F12 (GIBCO Biocult Europe, Breda, The Netherlands) containing 0.1% BSA, l-glutamine, fungizone (0.5 mg/L), and penicillin (105 U/L) (Bristol-Myers Squibb, Woerden, The Netherlands) after an initial incubation period of 24 h in 10% FCS to allow the cells to attach.
DMS-79 cells were cultured in RPMI 1640 (GIBCO Biocult Europe, Breda, The Netherlands) containing 10% heat-inactivated (Hi)-FCS, l-glutamine, and penicillin (105 U/L) (Bristol-Myers Squibb, Woerden, The Netherlands). Cells were harvested with pipetting and cell viability always exceeded 80%. All cell line proliferation experiments were performed at least four times.
Drugs and Reagents
Ketoconazole was purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands) and dissolved in ethanol as a 10−2 M stock solution (stored at − 20 °C) and diluted in ethanol prior to use. We tested concentrations ranging between 10−5 and 10−7 M in BON-1 cells and concentrations ranging between 5 × 10−5 and 5 × 10−7M in DMS-79 cells. Control wells were treated only with vehicle only (ethanol). We used different concentrations for both cell lines because the cell lines showed a different sensitivity to ketoconazole in pilot experiments (not shown). For both cell lines, all experiments included the clinically relevant concentrations of ketoconazole.
Octreotide and pasireotide were obtained from Novartis Pharma (Basel, Switzerland) and diluted in medium until a final concentration of 10−8 M.
Cell Proliferation Assay
Measurement of Total DNA Content (Measure of Total Cell Number)
Cells were plated in 1 mL medium in 24-well plates at a density necessary to obtain a 65–70% cell confluence in the control groups at the end of the experiment (50,000 cells/well for 3 days and 10,000 cells/well for 7 days in BON-1 cells; 150,000 cells/well for 3 days and 75,000 cells/well for 7 days in DMS-79 cells). Twenty-four hours later, the medium was refreshed and increasing concentrations of ketoconazole, alone or combined with SSA, were added to the cells.
After 3 and 7 days of treatment, the cells were harvested for DNA measurement, as a measure of cell number. For 7 days, treatment medium and drugs were refreshed at day 3. The procedure for the DNA measurement has been previously described in detail [22, 23]. Briefly, the cells were treated with 150 μL of ammonia solution (1 mol/L)-Triton X 100 (0.2% v/v) for 15 min. Thereafter, sonification was performed (Soniprep 150; amplitude 1400 μm). Subsequently, 1 mL of assay buffer (100 mM NaCl, 100 mM EDTA, 10 mM Tris; pH 7.0) was added. For DNA measurement, 20 μL of the solution was mixed with 200 μL of Hoechst dye H33258 solution (1 μg/mL). Fluorescence was measured with the excitation and emission wavelengths set at 350 and 455 nM respectively. The fluorescence of experimental samples was referenced to a standard curve of calf thymus DNA (type II, no D-3636; Sigma-Aldrich (Zwijndrecht, The Netherlands).
Soft Agar Colony Forming Assay
The effect of ketoconazole on colony formation was evaluated using a soft agar colony forming assay. The method was according to a previously described protocol . The number of cells plated in the upper layer of 0.3% agar (Sigma Aldrich) was 15,000 for DMS-79 and 5000 for BON-1. After 7 and 14 days, 1 mL of medium without or with increasing concentrations of ketoconazole (range between 5 × 10−5 and 10−6 M) was added. Adequate colony formation was achieved around day 21. At this time point, the cells were stained with 200 μL nitroblue tetrazolium chloride solution (1 mg/mL; Sigma) per well and overnight incubation at 37 °C. Once colonies were stained, photomicrographs were taken with a Multimage Light Cabinet (Alpha Innotech Corporation, USA). Analysis of colony number and size was performed using the software program ImageJ. Only colonies with a size ≥ 75 μM were analyzed.
mRNA expression of chromoganin A (CgA) in BON-1 cells, proopiomelanocortin (POMC) in DMS-79 cells, and somatostatin receptors (SST1, SST2, SST3, SST5) in both cell lines was evaluated by quantitative RT-PCR. We used a previously described method . In short, poly(A+) mRNA was isolated using Dynabeads Oligo (Deoxythymidine)25 (Dynal AS, Oslo, Norway). The poly(A+) mRNA was eluted in H2O (65 °C) twice for 2 min each and used for cDNA synthesis in a Tris buffer [50 mm Tris-HCl (pH 8.3), 100 mm KCl, 4 mm dithiothreitol, and 10 mm MgCl2] with 10 U ribonuclease inhibitor, 2 U avian myeloblastosis virus Super Reverse Transcriptase, and 1 mm of each deoxynucleotide triphosphate in a final volume of 40 μL. This mixture was incubated for 1 h at 42 °C, and the resulting cDNA was diluted fivefold in 160 μL sterile H20. The total reaction volume (25 μL) consisted of 10 μL cDNA and 15 μL TaqMan Universal PCR Mastermix (Applied Biosystems, Branchburg, NJ). Primers were used at final concentration of 300 nm and probe at 200 nm. Real-time qPCR was performed in 96-well optical plates with the TaqMan Gold nuclease assay (Applied Biosystems, Roche) and the ABI Prism 7700 Sequence Detection System (PerkinElmer, Foster City, CA). After two initial heating steps at 50 °C (2 min) and 95 °C (10 min), samples were subjected to 40 cycles of denaturation at 95 °C (15 s) and annealing at 60 °C (60 s). All samples were assayed in duplicate. Dilution curves were constructed to calculate PCR efficiencies (E) for every primer-probe set . To exclude genomic DNA contamination in the RNA, the cDNA reactions were also performed without reverse transcriptase and amplified with each primer pair. To exclude contamination of the PCR mixtures, the reactions were also performed in the absence of a cDNA template.
CgA and POMC mRNA were normalized to the housekeeping genes HPRT1, beta-glucuronidase (GUSB), and beta-actine (ACTB/ACTB) expression levels using the method of Vandesompele ; somatostatin receptors were normalized against HPRT1. CgA, POMC, GUSB, ACTB primer/probes were purchased from Thermo Fisher Scientific, The Netherlands, while the used sequence of somatostatin receptors and HPRT1 has been previously described . PCR efficiencies were as follows: CgA: 1.95, POMC: 1.92, SST1: 2, SST2: 1.91, SST3: 1.92, SST5: 1.92, HPRT1: 1.91, ACTB: 1.91, GUSB: 2. The relative expression of genes was calculated using the comparative threshold method, 2−ΔC1 , after efficiency correction  of target and reference gene transcripts (HPRT, GUS-B, ACTB). All experiments were performed at least twice with four replicates.
Cell Cycle Assay—Apoptosis Analysis
Cells were plated in 12-well plates at the density necessary to obtain a 65–70% cell confluence in the control groups at the end of the experiment. Twenty-four hours later, ketoconazole was added to wells in triplicate. In each cell line, the effects of ketoconazole on cell cycle were tested in three concentrations (5 × 10−6, 10−6, and 5 × 10−5 M in DMS-79; 10−6, 5 × 10−6, and 10−5 M in BON-1 cells) on cell proliferation after 7 days of treatment. We evaluated the effects of the compounds on cell cycle and apoptosis after 72 h of treatment. Following treatment, cells were harvested and collected by centrifugation. For cell cycle, cells were fixed in 70% ice-cold ethanol, followed by an overnight incubation at − 20 °C. Samples were measured using the Muse™ cell cycle kit (Merck) and prepared according to the manufacturer’s protocol. For apoptosis measurement, cells were resuspended in 100 μL PBS/1% FCS, according to the protocol provided by the manufacturer. A commercially available kit was used (Muse™ annexin V dead cell). All measurements were performed using the Muse® Cell Analyzer (Merck). Apoptosis was measured using a commercially available ELISA (Cell Death Detection ELISA Plus, Roche, The Netherlands) according to the manufacturer’s protocol. Lactate dehydrogenase LDH release was measured using a kit (pierce LDH cytotoxicity assay kit, Thermo scientific, The Netherlands) and samples were treated according to the protocol provided by the manufacturer. All experiments were performed at least three times using three replicates.
ACTH Secretion Assay
In DMS-79 cells, we evaluated the effects of ketoconazole alone and in combination with octreotide/pasireotide on ACTH secretion after 3 and 7 days of treatment. Cells were plated in 24-well plates and treated as described earlier for the cell proliferation assay. The experiment was performed twice. ACTH levels were determined using a chemiluminescent immunometric assay in an IMMULITE® 2000 system. ACTH secretion values were normalized for cell amount per well (DNA). The sensitivity of this assay ranged between 1.1 and 270 pmol/L. Untreated control values were within this range. All experiments were performed at least two times using four replicates.
Chromogranin A and Serotonin Secretion Assay
BON-1 cells were plated in 24-well plates using a medium containing 0.1% BSA, and treated as described earlier for the cell proliferation assay. Medium was collected from each well, to samples for the serotonin ELISA ascorbic acid was added (final concentration 0.1%). A commercially available human chromogranin An ELISA kit (Epitope diagnostics Inc., San Diego CA, USA) and a serotonin high sensitive ELISA (IBL International, Hamburg Germany) were used following the manufacturer’s instructions. The DNA content per well was used to correct both serotonin and CgA absolute values. All experiments were performed at least two times using four replicates.
For the statistical analysis, statistical software of GraphPad Prism version 5 (GraphPhad Software, San Diego, CA) was used. Between-group comparisons were analyzed by the Mann–Whitney U test (nonparametric data), or the Kruskal–Wallis test (nonparametric data, when we compared more than two groups). Differences were taken to be statistically significant at p < 0.05. Results are expressed as mean ± S.E.M. and percentages. Log transformation was used for calculating the IC50.
Effects of Ketoconazole
In BON-1 cells, the inhibitory effect of ketoconazole ranged between 41.03% at the maximal dose (10−5 M; p < 0.0001) and 19.1% at a dose of 5 × 10−6 M (p < 0.01) after 3 days of treatment (Fig. 1b). After 7 days, the growth inhibitory effect increased to 95.23% and 74.82% with ketoconazole 10−5 M and 5 × 10−6 M respectively (p < 0.0001) (Fig. 1b). The IC50 after 7 days of incubation was 7.7 × 10−6 M (95%CI 3.8 × 10−6–1.6 × 10−5 M). Ketoconazole (10−5 M and 5 × 10−6 M) significantly inhibited the number (88.31–52.19%, respectively). Only ketoconazole 10−5 M decreased the colony size of this cell line in agar (21.2%) (Fig. 2b). Ketoconazole 5 × 10−5 M completely abolished BON-1 colony formation.
Effect of Ketoconazole in Combination with Octreotide and Pasireotide
In BON-1 cells, octreotide slightly decreased cell growth by 9.4% (p < 0.05) after 3 days of treatment only (Fig. 3c, left panel), whereas pasireotide slightly inhibited cell growth by 13.5% (p < 0.01) at day 7 (Fig. 3d, left panel). In combination with pasireotide and octreotide, ketoconazole appeared slightly less effective at high dose ketoconazole (Fig. 3c and d, right panels).
Somatostatin Receptor Subtype Expression
The relative mRNA expression of somatostatin receptor subtypes was evaluated in both cell lines (Supplementary Figure 1). SST1 and SST5 expression in DMS-79 was lower compared with BON-1 cells. Rank order of expression in DMS-79 was SST1 = SST2 > SST3 > SST5 and for BON-1 SST1 > SST5> > SST2 > SST3.
In BON-1 cells, the highest ketoconazole concentration tested (10−5 M) induced a significant increase in early apoptosis, as well as late apoptosis (p < 0.0001). Consequently, the percentage of live and dead cells decreased (Fig. 4b). In order to confirm these results, the percentage of LDH release was determined. After 3 days of treatment with ketoconazole 10−5 M, LDH increased by approximately 50%, combined with a threefold increase in apoptosis/DNA ratio (p < 0.05; Fig. 4d).
Cell Cycle Progression
In BON-1 cell line, ketoconazole (10−5–5 × 10−6 M) induced a statistical significant G0/G1-phase increase (p < 0.0001, p < 0.01 respectively), accompanied by a decrease in G2-phase (p < 0.0001; Fig. 5b).
Chromogranin A and POMC Expression
Ketoconazole did not have a statistically significant effect on POMC mRNA expression in DMS cells (Supplemental Figure 2A) nor on CgA mRNA expression in BON-1 cells (Supplemental Figure 2B) after 3 days of treatment at any of the doses tested.
ACTH and Serotonin Secretion
The absolute production of CgA in BON-1 cells decreased when cells were treated with high doses of ketoconazole (10−5–5 × 10−6 M). This effect remained when combined with pasireotide and octreotide (Supplementary Figure 4C). After calculating the CgA/DNA ratio, no statistically significant effect was observed after 3 days of treatment with ketoconazole alone or in combination with SSA (Fig. 7b).
In the present study, we evaluated the direct effects of ketoconazole in ACTH-producing and non-ACTH-producing NET cell lines. We examined effects on proliferation, mRNA expression, and secretion by ketoconazole as monotherapy, as well as in combination with SSA, the latter representing the recommended first-line therapy in non-functioning/functioning progressive G1/G2 NETs . Our results revealed a particular effect of ketoconazole on proliferation, cell cycle, apoptosis, and mRNA expression, which was slightly different between the evaluated NET cell lines.
Ketoconazole is widely used for medical treatment of CS . Apart from its inhibitory effect on steroidogenesis, ketoconazole may have direct antitumor effects as EAS cases have been described in which temporarily treatment with ketoconazole was followed by prolonged remission of hypercortisolemia . For this reason, previously non-described off target in vitro effects of ketoconazole were evaluated in this study. While the evaluation of the effects of ketoconazole was the primary aim of this study, its combination with SSA was assessed due to their applicability in the clinical practice. SSAs are first-line therapy in functionally active NETs, including those associated with the carcinoid syndrome and functional pancreatic neuroendocrine tumors (PNETs) [32, 33]. We used two different SSA based on the fact that their anti-proliferative effect may depend on the expression level and type of SSTs in the tumor . Since the affinity of pasireotide for SST5 is 30–40-fold higher when compared with octreotide , both SSA were selected for this study.
In our study, we included clinically relevant concentrations of ketoconazole, based on previous results in humans. Several studies report serum ketoconazole levels of 3.6 μg/mL and 6.5 μg/mL after the administration of 200 and 400 mg of ketoconazole respectively . The continuous administration of 400 mg/8 h resulted in serum ketoconazole levels of 2–9 μg/mL . Several effects in this study on the NET cell lines have been achieved with these ketoconazole concentrations (5.3 μg/mL ketoconazole corresponds to 10−5 M).
Sharma and Nieman described four patients with EAS with prolonged remission of hypercortisolism following treatment with ketoconazole alone or in combination with metyrapone and/or mitotane. In one patient, this was accompanied by increased ACTH levels indicating a direct, sustained suppressive effect on the adrenal cortex. In two other patients, however, ACTH levels were normal to low suggesting a direct effect of ketoconazole on ectopic ACTH-producing tumor cells . In this sense, we observed decreased cell growth in both ACTH-producing and non-ACTH-producing NET cell lines, when exposed to ketoconazole in pharmacological concentrations (10−5–5 × 10−6 M). Importantly, DMS-79 cells are slightly less sensitive than BON-1 cells, and required higher doses for obtaining similar inhibitory effects in monolayer cultures. In the colony forming assay ketoconazole at a dose between 10−5 and 5 × 10−6 M induced similar cytotoxic effects in both cell lines.
The mechanism of action of ketoconazole seems to be different in both cell lines. In BON-1 cells, ketoconazole has an apoptotic effect (especially increasing early apoptosis), whereas in DMS-79 cell line, the effect seems to be more cytotoxic.
Previous reports have described a cytotoxic effect of ketoconazole in prostate cancer, adrenal cancer, and male metastatic breast cancer cell lines with a dose- and time-dependent pattern at clinically feasible concentrations . In addition, it has been shown that ketoconazole decreased tumor surface area and tumor colonies in liver metastasis of human pancreatic adenocarcinoma in animal models . This antitumor action of ketoconazole is further confirmed in our study, in which ketoconazole inhibited not only the number of colonies, but also the colony size. Due to its androgen lowering properties, ketoconazole is also evaluated as a potential treatment in other neoplasms such as prostate cancer . In these patients, the drug is administered at high doses (400 mg/8 h/day), in combination with hydrocortisone . Approximately, 27–60% of treated patients show up to 50% decrease in prostate antigen without receiving concomitant anti-androgen treatment. In addition, those patients that respond to treatment and do not have metastatic disease showed prolonged responses even after 7 years [40, 41]. Related to this, preliminary reports have suggested that the use of ketoconazole (600 mg/day) combined with docetaxel has a significant antitumor effect in castration-resistant prostate cancer patients . The cell growth inhibitory effects observed in our study suggest that an off target direct antitumor action of ketoconazole may be involved in the sustained remission which is sometimes observed in patients with ectopic ACTH secreting NET that are treated with this drug .
Differences observed in sensitivity to ketoconazole between both cell lines may be related to the heterogeneity of NETs . Tumor heterogeneity may explain different clinical responses to therapeutic options, including SSA and peptide receptor radionuclide therapy, as well as molecular targeted therapies [43, 44, 45]. In this sense, tumor heterogeneity affects clinical management and decision-making in NETs . Additionally, tumor response may differ according to the primary tumor localization and tumor load . DMS-79 and BON-1 are lung- and pancreas-derived cell lines, respectively. Furthermore, tumor cell characteristics were different; BON-1 cells attach to the culture plate surface, while DMS-79 grow in suspension and form small aggregates. Moreover, we observed a different somatostatin receptor expression pattern between both cell lines. Similar findings may be observed in other functional pathways that could also explain differences in the response of both cell lines . Importantly, in the colony formation assay, DMS-79 cells were similarly sensitive to the effects of ketoconazole compared with BON-1 cells.
Focusing on treatment of NETs, it is already known that SSA have antitumor effects in patients with NET and that they are useful for symptoms control and disease stabilization [31, 49, 50]. Despite this, in vitro findings reveal a weak effect of SSA on cell proliferation . In our study, we observed only a very weak anti-proliferative effect of octreotide after 3 days and of pasireotide after 7 days of treatment, which is concordant with reports in literature . The response to pasireotide after 7 days in BON-1 cells is probably related to the high expression of SST1 and SST5 receptors in this cell line. Interestingly, in BON-1 cells, the effectiveness of ketoconazole in combination with SSA on cell proliferation seems to be slightly decreased.
Our results on apoptosis are concordant with previous studies in other cell line models. Ho et al. reported apoptosis induced by ketoconazole in human colorectal and hepatocellular carcinoma cell lines through the p53 pathway (increased bax and decreased bcl-2 gene products) with minimal ketoconazole concentrations of 5 μg/mL . Similarly, Won et al. suggested that ketoconazole could increase apoptosis and decrease cell viability in rats through reactive oxygen species (ROS) in rat cardiomyocytes . Some other signaling routes have been proposed for explaining the apoptotic effect of ketoconazole, including the JNK phosphorylation in human osteosarcoma . Ketoconazole, when combined with terfenadine, seems to potentiate the inhibition of cytochrome p450 3A4 in human cancer cell lines .
When evaluating cell cycle, published results are contradictory. Forgue-Lafitte et al. reported decreased cell number in S phase and a corresponding increase in G0-G1 phases in colon cancer cells treated with ketoconazole . In contrast, Chen et al. described G0/G1 arrest in human colorectal and hepatocellular cell lines . However, in our study, we observed in both cell lines a significant increase in G0/G1 phase, which was accompanied with an arrest of G2/M phases in BON-1 cells. These results suggest that ketoconazole may have a differential mechanism of action in different tumor cell lines.
When analyzing secretion, ketoconazole did not affect serotonin secretion, but the effect of pasireotide on serotonin production is relevant and stable after its combination with ketoconazole, suggesting a therapeutic indication for pasireotide in (a subset of) patients with carcinoid syndrome or functioning NETs with liver metastasis, refractory to classical SSA. Interestingly, pasireotide had no effect on CgA secretion, suggesting that serotonin may be a better marker of secretion. Pasireotide has a higher binding affinity for SST1, SST3, and SST5 when compared with octreotide, as well as a slightly lower affinity for SST2 . Moreover, as we did not observe any effect of ketoconazole alone or combined with SSA on CgA secretion after correcting for its effect on cell number, it is likely that CgA is related to tumor growth and less to tumor secretion capacity .
Changes on hormone secretion by ketoconazole have been previously described. Ketoconazole increases the spontaneous and stimulated release of prolactin in normal and tumoral rat pituitary cells , and decreases the ACTH production in human thymic carcinoid cells . It has been also hypothesized that ketoconazole could affect tumoral ACTH and cyclic ACTH secretion in vivo . In our study, however, we did not observe a direct inhibitory effect of clinically feasible concentrations of ketoconazole on ACTH production by DMS-79 cells (corrected for the effect of ketoconazole on cell growth), suggesting that the effect of ketoconazole is primarily cytotoxic. The absence of an effect on ACTH production may also be reflected by the fact that ketoconazole did not affect POMC mRNA expression.
In summary, this study provides a primary comprehensive mapping of the effect of ketoconazole on NET cell lines, suggesting a potential effect of ketoconazole on cell proliferation, apoptosis, and cell cycle. This antitumor effect appears not tumor cell type–specific, since it was observed in both ACTH secreting and non-ACTH secreting NET cells. A direct antitumor action of ketoconazole may be an explanation for prolonged remission of hypercortisolemia observed in some patients with EAS and may have an added off target therapeutic value next to its adrenal-suppressive effects. Additional studies, including primary (ACTH-producing) NET cultures, are required to confirm and further extend these results.
- 1.Hofland J et al (2018) Recent developments in the diagnosis and therapy of well-differentiated neuroendocrine tumours. Neth J Med 76(3):100–108Google Scholar
- 2.Fraenkel M et al (2014) Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer 21(3):R153–R163Google Scholar
- 3.Herrera-Martinez AD, Padillo Cuenca JC, Bahamondes Opazo R, Barrera Martín A, Rebollo Roman A, Díaz Iglesia C, Gálvez Moreno MA (2017) ACTH producing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1. J Pancreas 02:175–180Google Scholar
- 4.Kaltsas G, Androulakis II, de Herder WW, Grossman AB (2010) Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer 17(3):R173–R193Google Scholar
- 5.Fazel P, Ganesa P, Mennel RG, Austin NA (2008) The ectopic adrenocorticotropic hormone syndrome in carcinoid tumors. Proc (Bayl Univ Med Cent) 21(2):140–143Google Scholar
- 6.Kamp K, Alwani RA, Korpershoek E, Franssen GJH, de Herder WW, Feelders RA (2016) Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors. Eur J Endocrinol 174(3):271–280Google Scholar
- 7.Kondo T et al (2010) A case of ectopic adrenocorticotropic hormone-producing pancreatic neuroendocrine tumor with multiple liver metastases. Endocr J 57(3):229–236Google Scholar
- 8.Lacroix A, Feelders RA, Stratakis CA, Nieman LK (2015) Cushing’s syndrome. Lancet 386(9996):913–927Google Scholar
- 9.Wajchenberg BL et al (1994) Ectopic adrenocorticotropic hormone syndrome. Endocr Rev 15(6):752–787Google Scholar
- 10.Nieman LK, Biller BMK, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A (2015) Treatment of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 100(8):2807–2831Google Scholar
- 11.Isidori AM, Kaltsas GA, Pozza C, Frajese V, Newell-Price J, Reznek RH, Jenkins PJ, Monson JP, Grossman AB, Besser GM (2006) The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab 91(2):371–377Google Scholar
- 12.Alberda WJ, van Eijck CHJ, Feelders RA, Kazemier G, de Herder WW, Burger JWA (2012) Endoscopic bilateral adrenalectomy in patients with ectopic Cushing’s syndrome. Surg Endosc 26(4):1140–1145Google Scholar
- 13.Feelders RA, Hofland LJ (2013) Medical treatment of Cushing’s disease. J Clin Endocrinol Metab 98(2):425–438Google Scholar
- 14.Beardwell CG, Adamson AR, Shalet SM (1981) Prolonged remission in florid Cushing’s syndrome following metyrapone treatment. Clin Endocrinol 14(5):485–492Google Scholar
- 15.Loh KC, Gupta R, Shlossberg AH (1996) Spontaneous remission of ectopic Cushing’s syndrome due to pheochromocytoma: a case report. Eur J Endocrinol 135(4):440–443Google Scholar
- 16.Sharma ST, Nieman LK (2012) Prolonged remission after long-term treatment with steroidogenesis inhibitors in Cushing’s syndrome caused by ectopic ACTH secretion. Eur J Endocrinol 166(3):531–536Google Scholar
- 17.Steen RE, Kapelrud H, Haug E, Frey H (1991) In vivo and in vitro inhibition by ketoconazole of ACTH secretion from a human thymic carcinoid tumour. Acta Endocrinol 125(3):331–334Google Scholar
- 18.Lamberts SW et al (1994) A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing’s syndrome. J Clin Endocrinol Metab 78(1):17–19Google Scholar
- 19.de Herder WW, van der Lely AJ, Lamberts SW (1996) Somatostatin analogue treatment of neuroendocrine tumours. Postgrad Med J 72(849):403–408Google Scholar
- 20.de Herder WW, Krenning EP, Malchoff CD, Hofland LJ, Reubi JC, Kwekkeboom DJ, Oei HY, Pols HAP, Bruining HA, Nobels FRE, Lamberts SWJ (1994) Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing’s syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. Am J Med 96(4):305–312Google Scholar
- 21.Uwaifo GI, Koch CA, Hirshberg B, Chen CC, Hartzband P, Nieman LK, Pacak K (2003) Is there a therapeutic role for octreotide in patients with ectopic Cushing’s syndrome? J Endocrinol Investig 26(8):710–717Google Scholar
- 22.Hofland LJ, van Koetsveld PM, Lamberts SW (1990) Percoll density gradient centrifugation of rat pituitary tumor cells: a study of functional heterogeneity within and between tumors with respect to growth rates, prolactin production and responsiveness to the somatostatin analog SMS 201-995. Eur J Cancer 26(1):37–44Google Scholar
- 23.Downs TR, Wilfinger WW (1983) Fluorometric quantification of DNA in cells and tissue. Anal Biochem 131(2):538–547Google Scholar
- 24.Borowicz S, Van Scoyk M, Avasarala S, Karuppusamy Rathinam MK, Tauler J, Bikkavilli RK, Winn RA (2014) The soft agar colony formation assay. J Vis Exp 92(E51998). https://doi.org/10.3791/51998
- 25.Ferone D, Pivonello R, van Hagen PM, Dalm VASH, Lichtenauer-Kaligis EGR, Waaijers M, van Koetsveld PM, Mooy DM, Colao A, Minuto F, Lamberts SWJ, Hofland LJ (2002) Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. Am J Physiol Endocrinol Metab 283(5):E1056–E1066Google Scholar
- 26.Rasmussen R (2001) Quantification on the LightCycler. In: Meuer S, Wittwer C, Nakagawara K (eds) Rapid cycle real-time PCR, methods and applications. Springer Press, Heidelberg, pp 21–34Google Scholar
- 27.Vandesompele J et al (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3(7):RESEARCH0034Google Scholar
- 28.de Bruin C, Pereira AM, Feelders RA, Romijn JA, Roelfsema F, Sprij-Mooij DM, van Aken MO, van der Lelij AJ, de Herder WW, Lamberts SWJ, Hofland LJ (2009) Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab 94(4):1118–1124Google Scholar
- 29.Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3(6):1101–1108Google Scholar
- 30.Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45Google Scholar
- 31.Oberg K et al (2012) Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii124–vii130Google Scholar
- 32.Pavel M, O’Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, Öberg K, all other Vienna Consensus Conference participants (2016) ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103(2):172–185Google Scholar
- 33.Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Klöppel G, Reed N, Kianmanesh R, Jensen RT, all other Vienna Consensus Conference participants (2016) ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103(2):153–171Google Scholar
- 34.Jensen RT (2000) Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment. Curr Opin Oncol 12(4):368–377Google Scholar
- 35.Bruns C et al (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146(5):707–716Google Scholar
- 36.Van Tyle JH (1984) Ketoconazole: mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy 4:343–347Google Scholar
- 37.Heyns W, Drochmans A, van der Schueren E, Verhoeven G (1985) Endocrine effects of high-dose ketoconazole therapy in advanced prostatic cancer. Acta Endocrinol 110(2):276–283Google Scholar
- 38.Rochlitz CF et al (1988) Cytotoxicity of ketoconazole in malignant cell lines. Cancer Chemother Pharmacol 21(4):319–322Google Scholar
- 39.Tzanakakis GN, Agarwal KC, Vezeridis MP (1990) Inhibition of hepatic metastasis from a human pancreatic adenocarcinoma (RWP-2) in the nude mouse by prostacyclin, forskolin, and ketoconazole. Cancer 65(3):446–451Google Scholar
- 40.Huguet Pérez J, Maroto Rey P, Palou Redorta J, Villavicencio Mavrich H (2006) Cáncer de próstata hormonorresistente. Cambios en las estrategias terapéuticas desde la demostración de la utilidad de la quimioterapia. Actas Urol Esp 30(2):123–133Google Scholar
- 41.Scholtz M, Jennrich R, Strum S, Brosman S, Johnson H, Lam R (2005) Long-term outcome with androgen independent prostate cancer treated with ketoconazole and hidrocortisone. J Urol 173(6):1947–1952Google Scholar
- 42.Figg WD, Woo S, Zhu W, Chen X, Ajiboye AS, Steinberg SM, Price DK, Wright JJ, Parnes HL, Arlen PM, Gulley JL, Dahut WL (2010) A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. J Urol 183(6):2219–2226Google Scholar
- 43.Ianniello A, Sansovini M, Severi S, Nicolini S, Grana CM, Massri K, Bongiovanni A, Antonuzzo L, di Iorio V, Sarnelli A, Caroli P, Monti M, Scarpi E, Paganelli G (2016) Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. Eur J Nucl Med Mol Imaging 43(6):1040–1046Google Scholar
- 44.Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, van Eijck CHJ, Franssen GJH, Krenning EP, Kwekkeboom DJ (2017) Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res 23(16):4617–4624Google Scholar
- 45.Yao JC, Lagunes DR, Kulke MH (2013) Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned. Oncologist 18(5):525–532Google Scholar
- 46.Cives M, Soares HP, Strosberg J (2016) Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Curr Opin Oncol 28(4):359–366Google Scholar
- 47.Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP (2005) Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23(12):2754–2762Google Scholar
- 48.Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F (2008) Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 15(1):257–266Google Scholar
- 49.Caplin ME, Pavel M, Ruszniewski P (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371(16):1556–1557Google Scholar
- 50.Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27(28):4656–4663Google Scholar
- 51.Ho YS, Tsai PW, Yu CF, Liu HL, Chen RJ, Lin JK (1998) Ketoconazole-induced apoptosis through P53-dependent pathway in human colorectal and hepatocellular carcinoma cell lines. Toxicol Appl Pharmacol 153(1):39–47Google Scholar
- 52.Won KJ, Lee KP, Yu S, Lee D, Lee DY, Lee HM, Kim J, Jung SH, Baek S, Kim B (2015) Ketoconazole induces apoptosis in rat cardiomyocytes through reactive oxygen species-mediated Parkin overexpression. Arch Toxicol 89(10):1871–1880Google Scholar
- 53.Lin KL, Huang CC, Cheng JS, Tsai JY, Lu YC, Chang HT, Jan CR (2009) Ketoconazole-induced JNK phosphorylation and subsequent cell death via apoptosis in human osteosarcoma cells. Toxicol in Vitro 23(7):1268–1276Google Scholar
- 54.Wang YJ, Yu CF, Chen LC, Chen CH, Lin JK, Liang YC, Lin CH, Lin SY, Chen CF, Ho YS (2002) Ketoconazole potentiates terfenadine-induced apoptosis in human Hep G2 cells through inhibition of cytochrome p450 3A4 activity. J Cell Biochem 87(2):147–159Google Scholar
- 55.Forgue-Lafitte ME et al (1992) Effects of ketoconazole on the proliferation and cell cycle of human cancer cell lines. Cancer Res 52(24):6827–6831Google Scholar
- 56.Chen RJ, Lee WS, Liang YC, Lin JK, Wang YJ, Lin CH, Hsieh JY, Chaing CC, Ho YS (2000) Ketoconazole induces G0/G1 arrest in human colorectal and hepatocellular carcinoma cell lines. Toxicol Appl Pharmacol 169(2):132–141Google Scholar
- 57.van der Hoek J, van der Lelij AJ, Feelders RA, de Herder WW, Uitterlinden P, Poon KW, Boerlin V, Lewis I, Krahnke T, Hofland LJ, Lamberts SW (2005) The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clin Endocrinol 63(2):176–184Google Scholar
- 58.Colombo B et al (2002) Chromogranin A expression in neoplastic cells affects tumor growth and morphogenesis in mouse models. Cancer Res 62(3):941–946Google Scholar
- 59.Drouhault R, Vacher P, David JP, Courtes AM, Vilayleck N, Dufy B (1989) Differential effects of ketoconazole on prolactin and growth hormone release by normal and tumoral rat anterior pituitary cells in vitro. Neuroendocrinology 50(5):513–518Google Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.